Zogenix, Inc. reported positive top-line results from its second confirmatory Phase 3 study (Study 1504) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of children and young adults with Dravet syndrome. The study results, which are consistent with those reported in Study 1, Zogenix’s first pivotal Phase 3 study, successfully met the primary endpoint and all key secondary endpoints, demonstrating that ZX008, at a dose of 0.5 mg/kg/day (maximum 20 mg/day), is superior to placebo when added to a stiripentol regimen.
July 12, 2018
March 20, 2019
Daylight Saving Time Transitions are Not Associated with Increased Seizure Incidence
Despite expectations that circadian and sleep disruption related to daylight savings time transitions would increase the incidence of seizures, this study found little substantive evidence for such an association in this large, longitudinal cohort.